Pub. Date : 1999 Feb
PMID : 10051052
6 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | This finding was accompanied by a corresponding reduction of the inactive glucuronide metabolite of MPA (MPAG) in patients, suggesting that tacrolimus may effect the conversion of MPA to MPAG by the enzyme UDP-glucuronosyltransferase (UDPGT). | Tacrolimus | UDP glucuronosyltransferase family 1 member A4 | Homo sapiens |
| 2 | This finding was accompanied by a corresponding reduction of the inactive glucuronide metabolite of MPA (MPAG) in patients, suggesting that tacrolimus may effect the conversion of MPA to MPAG by the enzyme UDP-glucuronosyltransferase (UDPGT). | Tacrolimus | UDP glucuronosyltransferase family 1 member A4 | Homo sapiens |
| 3 | The addition of clinically relevant concentrations of CsA (200-1,000 ng/mL) or tacrolimus (10-25 ng/mL) resulted in a dose-dependent inhibition of the UDPGT enzyme by both agents with tacrolimus, which was approximately 60-fold more efficient as an inhibitor. | Tacrolimus | UDP glucuronosyltransferase family 1 member A4 | Homo sapiens |
| 4 | The addition of clinically relevant concentrations of CsA (200-1,000 ng/mL) or tacrolimus (10-25 ng/mL) resulted in a dose-dependent inhibition of the UDPGT enzyme by both agents with tacrolimus, which was approximately 60-fold more efficient as an inhibitor. | Tacrolimus | UDP glucuronosyltransferase family 1 member A4 | Homo sapiens |
| 5 | The calculated inhibition constants (KI) of tacrolimus and CsA for the purified UDPGT were 27.3+/-5.6 ng/ml and 2,518+/-1473 ng/ml. | Tacrolimus | UDP glucuronosyltransferase family 1 member A4 | Homo sapiens |
| 6 | This finding suggested that the significantly more efficient inhibition of UDPGT by tacrolimus may occur by a more complicated mechanism that is yet to be determined. | Tacrolimus | UDP glucuronosyltransferase family 1 member A4 | Homo sapiens |